Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma ...

THE SKNJCT-003 CLINICAL STUDY EXPANSION INTO THE UNITED KINGDOM TO FURTHER ENABLE GLOBAL PATIENT RECRUITMENT AND CLINICAL DATASET TOWARD A PIVOTAL STUDY PROGRAM PHILADELPHIA, PA / ACCESS Newswire / ...
Agence France-Presse

Indero Announces Breakthrough Method for Early-Phase Evaluation of Topical Drugs Using Quantitative Gene Expression

Indero is proud to announce the successful completion of an internally funded study that introduces a novel approach to evaluating topical new chemical entities (NCE) in early-phase clinical research.
Pharmabiz

Merck’s Winrevair meets primary endpoint in phase 2 CADENCE study in adults with CpcPH due to heart failure with preserved ejection fraction

Rahway, New Jersey Wednesday, November 19, 2025, 10:00 Hrs [IST] ...

Celltrion ramps up US plant upgrade to preempt tariff risks

Celltrion will invest 5.4 trillion won ($3.7 billion) in expanding its recently acquired production site in the United States ...
MyChesCo on MSN

Prelude Advances Two Novel Cancer Programs as Cash Runway Extends Into 2027

Prelude Therapeutics Incorporated (Nasdaq: PRLD) reported third-quarter 2025 financial results and outlined key progress ...

RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck

ORLANDO, FL / ACCESS Newswire / November 14, 2025 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today congratulated its ...